Table 9.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1996 to 2005

Recipients with Liver Transplants

  Year of Transplant
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 4,083 4,188 4,516 4,751 4,995 5,191 5,331 5,673 6,169 6,441
Tx with Antirejection Treatments 1,304 1,324 1,184 1,466 1,500 1,420 1,301 1,042 992 1,037
Antibodies Any in Category 13.3% 12.1% 13.1% 12.5% 14.5% 16.8% 17.5% 17.9% 21.2% 14.9%
Atgam/NRATG/NRATS 2.1% 1.4% 1.4% 0.7% 0.5% 0.5% 0.6% 0.8% 0.8% 1.1%
OKT3 11.9% 11.1% 9.7% 6.8% 6.3% 6.7% 6.0% 5.4% 5.7% 4.5%
Thymoglobulin 0.0% 0.0% 0.3% 1.4% 3.2% 5.1% 5.6% 7.0% 11.3% 7.5%
Zenapax 0.0% 0.2% 0.9% 1.7% 2.4% 1.6% 1.9% 1.4% 3.4% 0.8%
Simulect 0.0% 0.1% 1.2% 3.1% 3.1% 4.2% 4.0% 3.1% 0.7% 0.9%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.6% 2.0% 1.4% 1.0%
Corticosteroids Any in Category 83.7% 84.1% 87.3% 89.5% 90.7% 89.0% 90.3% 91.6% 88.6% 91.5%
Steroids 83.7% 84.1% 87.3% 89.5% 90.7% 89.0% 90.3% 91.6% 88.6% 91.5%
Antimetabolites Any in Category 0.2% 0.7% 0.3% 0.2% 0.1% 0.1% 0.0% 0.1% 0.0% 0.3%
Cytoxan 0.2% 0.7% 0.3% 0.2% 0.1% 0.1% 0.0% 0.1% 0.0% 0.2%
Methotrexate 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1%


Source: OPTN/SRTR Data as of May 1, 2007.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.